Literature DB >> 7862923

Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report.

V Raitasuo1, R Lehtovaara, M O Huttunen.   

Abstract

Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine. This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms. None of the patients showed any clinical deteriotation during the following 3-6 months. The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7862923     DOI: 10.1007/bf02244881

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  Determination of clozapine in human serum by capillary gas chromatography.

Authors:  K Richter
Journal:  J Chromatogr       Date:  1988-12-30

2.  Measurement of carbamazepine and its epoxide metabolite by high-performance liquid chromatography, and a comparison of assay techniques for the analysis of carbamazepine.

Authors:  G W Mihaly; J A Phillips; W J Louis; F J Vajda
Journal:  Clin Chem       Date:  1977-12       Impact factor: 8.327

3.  Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia.

Authors:  R Kidron; I Averbuch; E Klein; R H Belmaker
Journal:  Biol Psychiatry       Date:  1985-02       Impact factor: 13.382

4.  Measurement of haloperidol and reduced haloperidol in human plasma using reversed-phase high-performance liquid chromatography.

Authors:  R L Miller; C L DeVane
Journal:  J Chromatogr       Date:  1986-01-24

5.  Carbamazepine and plasma levels of clozapine.

Authors:  V Raitasuo; R Lehtovaara; M O Huttunen
Journal:  Am J Psychiatry       Date:  1993-01       Impact factor: 18.112

6.  Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.

Authors:  J G Larkin; P J McKee; G Forrest; G H Beastall; B K Park; J I Lowrie; P Lloyd; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 7.  Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.

Authors:  S M Grant; D Faulds
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

8.  Solid-phase extraction and high-performance liquid chromatographic method for chlorpromazine and thirteen metabolites.

Authors:  C S Smith; S L Morgan; S V Greene; R K Abramson
Journal:  J Chromatogr       Date:  1987-12-25
  8 in total
  9 in total

Review 1.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 2.  Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.

Authors:  E Spina; F Pisani; E Perucca
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 3.  Oxcarbazepine: an update of its efficacy in the management of epilepsy.

Authors:  K Wellington; K L Goa
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 4.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 5.  Interactions between antiepileptic and antipsychotic drugs.

Authors:  Frank M C Besag; David Berry
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 6.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

Review 7.  Clinical pharmacokinetics of oxcarbazepine.

Authors:  Theodor W May; Elisabeth Korn-Merker; Bernhard Rambeck
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 8.  Carbamazepine for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John McGrath
Journal:  Cochrane Database Syst Rev       Date:  2014-05-02

Review 9.  A Case Report of Catatonia and Neuroleptic Malignant Syndrome With Multiple Treatment Modalities: Short Communication and Literature Review.

Authors:  Yu-Jie Chiou; Yu Lee; Chin-Chuen Lin; Tiao-Lai Huang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.